Mechanisms Controlling PD-L1 Expression in Cancer

The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene) receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 gene), is a major co-inhibitory checkpoint signaling that controls T cell activities. Various types of ca...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Molecular cell Ročník 76; číslo 3; s. 359
Hlavní autoři:	Cha, Jong-Ho, Chan, Li-Chuan, Li, Chia-Wei, Hsu, Jennifer L, Hung, Mien-Chie
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 07.11.2019
Témata:	Animals Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - genetics B7-H1 Antigen - immunology B7-H1 Antigen - metabolism Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology Biomarkers, Tumor - metabolism Gene Expression Regulation, Neoplastic Humans Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - genetics Neoplasms - immunology Neoplasms - metabolism Protein Processing, Post-Translational RNA Processing, Post-Transcriptional Signal Transduction Transcription, Genetic Tumor Escape
ISSN:	1097-4164, 1097-4164
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene) receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 gene), is a major co-inhibitory checkpoint signaling that controls T cell activities. Various types of cancers express high levels of PD-L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity. Blocking the PD-L1/PD-1 pathway has consistently shown remarkable anti-tumor effects in patients with advanced cancers and is recognized as the gold standard for developing new immune checkpoint blockade (ICB) and combination therapies. However, the response rates of anti-PD-L1 have been limited in several solid tumors. Therefore, furthering our understanding of the regulatory mechanisms of PD-L1 can bring substantial benefits to patients with cancer by improving the efficacy of current PD-L1/PD-1 blockade or other ICBs. In this review, we provide current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional, post-translational, and extracellular levels, and discuss the implications of these findings in cancer diagnosis and immunotherapy.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1097-4164 1097-4164
DOI:	10.1016/j.molcel.2019.09.030